Description

THE WORLD’S FIRST NEEDLE-FREE CONTINUOUS GLUCOSE MONITOR

Transdermal Diagnostics is a MedTech spin-out dedicated to developing and commercialising innovative technologies for needleless monitoring of health biomarkers in real-time. TD aims to reinvent patient care and lead a paradigm-shift from treatment to prevention. Currently, TD is developing the world’s first 100% needle-free wearable to help patients manage diabetes accurately and more effectively.

Diabetes is a global health crisis currently afflicting hundreds of millions of people and is projected to rise to 783 million by 2045. Commercial sugar monitors are unpleasant, expensive, inconvenient, and cause poor disease management, exposing patients to an increased risk of developing life-threatening co-morbidities and reducing overall life expectancy. TD is addressing this challenge by developing a wearable smart-patch for non-invasive and real-time monitoring of health biomarkers.

"We are excited to have investors like Elbow Beach Capital on board with a deep understanding of the transformative potential of Transdermal Diagnostics' technology platform. This funding round will kick-start our mission to revolutionise the prevention, diagnosis and management of chronic conditions, starting with diabetes" - Dr Luca Lipani, Founder & CEO of Transdermal Diagnostics

Year Invested

2022

Investment Category

Explore

Headquarters

Bath

Website

Transdermal Diagnostics

View Press Release